Voyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer
September 18 2017 - 9:00AM
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases announced today the appointment of
Matthew P. Ottmer as chief operating officer. Mr. Ottmer brings to
Voyager more than 18 years of biotechnology industry experience,
including executive leadership of business operations, product
development, and commercialization across multiple therapeutic
areas and all stages of development.
“We are very excited to welcome Matt to our
talented executive leadership team,” said Steven Paul, M.D.,
Voyager’s president and chief executive officer. “As Voyager’s
business continues to expand, the fast pace and complexity of our
expansion requires additional strong, cross-functional leadership
that Matt has demonstrated throughout his career. In addition
to leading strategy, program and alliance management, Matt will
oversee the commercial development plans of our lead and pipeline
programs, including new product planning for our Parkinson’s
disease program, which are critical, value-driving areas for the
company.”
Mr. Ottmer joins Voyager most recently from
Momenta Pharmaceuticals, Inc., where he was chief operating
officer, responsible for program and alliance management, research,
clinical development, pharmaceutical sciences and commercial
activities since late 2015. Prior to this role, Matt spent 16 years
at Biogen, Inc., in a variety of leadership roles, including as
senior vice president, strategy and emerging businesses, head of
Tysabri business, chief of staff to the chief executive officer,
president of Syntonix Pharmaceuticals, Inc. (a wholly owned
subsidiary of Biogen, now Bioverativ, Inc.), and vice president of
global operations. Matt received a Bachelor of Arts degree in
political science from the University of Michigan and a Master's in
Business Administration from Northwestern University’s Kellogg
School of Management.
“I am thrilled to join Voyager at this important
time during the company’s evolution,” said Matthew P. Ottmer,
Voyager’s chief operating officer. “Developing and implementing the
initial commercial strategy and planning for VY-AADC for
Parkinson’s disease is a top priority, especially as we approach
the start of the pivotal program, and I look forward to helping
advance our exciting pipeline programs as well.”
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases. Voyager is committed to advancing the
field of adeno-associated virus (AAV) gene therapy through
innovation and investment in vector engineering and optimization,
manufacturing and dosing and delivery techniques. Voyager’s
pipeline focuses on severe neurological diseases in need of
effective new therapies, including advanced Parkinson’s disease, a
monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia,
frontotemporal dementia, Alzheimer’s disease and severe, chronic
pain. Voyager has broad strategic collaborations with Sanofi
Genzyme, the specialty care global business unit of Sanofi, and the
University of Massachusetts Medical School. Founded by
scientific and clinical leaders in the fields of AAV gene therapy,
expressed RNA interference and neuroscience, Voyager Therapeutics
is headquartered in Cambridge, Massachusetts. For more
information, please visit www.voyagertherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“undoubtedly,” “project,” “intend,” “future,” “potential,” or
“continue,” and other similar expressions are intended to identify
forward-looking statements. For example, all statements Voyager
makes regarding the initiation, timing, progress and reporting of
results of its preclinical programs and clinical trials and its
research and development programs; its ability to advance its
AAV-based gene therapies into, and successfully initiate, enroll,
and complete, clinical trials; the potential clinical utility of
its product candidates; its ability to continue to develop its
product engine; its ability to add new programs to its pipeline;
its ability to enter into new partnerships or collaborations; its
expected cash, cash equivalents and marketable debt securities at
the end of a fiscal year and anticipation for how long expected
cash, cash equivalents and marketable debt securities will last;
and the timing or likelihood of its regulatory filings and
approvals are forward looking. All forward-looking statements are
based on estimates and assumptions by Voyager’s management that,
although Voyager believes to be reasonable, are inherently
uncertain. All forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those that Voyager expected. Such risks and
uncertainties include, among others, those related to the
initiation and conduct of preclinical studies and clinical trials,
the availability of data from clinical trials and the expectations
for regulatory submissions and approvals; the continued development
of the product engine; Voyager’s scientific approach and general
development progress; the availability or commercial potential of
Voyager’s product candidates; the sufficiency of cash resources;
and need for additional financing. These statements are also
subject to a number of material risks and uncertainties that are
described in Voyager’s most recent Annual Report on Form 10-K filed
with the Securities and Exchange Commission, as updated by its
subsequent filings with the Securities and Exchange Commission. Any
forward-looking statement speaks only as of the date on which it
was made. Voyager undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Relations:
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Sep 2023 to Sep 2024